Figure 3. Proportion of patients achieving ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMDs) from pre–double-blind treatment phase (DBTP) baseline.

Proportion of patients achieving (A) ≥50%; (B) ≥75%; and (C) 100% reduction in MMDs from the pre-DBTP (study) baseline to week 52.